{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-001451","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.346272+00:00","generated_at":"2026-06-04T08:54:22.785296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M","bullets":["Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.","Cash & equivalents $20.7M at Dec 31, 2023 (vs $10.9M end of 2022); received $13.0M milestone from Heska in Dec 2023.","Sold kits for over 58,000 Nu.Q Vet Cancer Tests in 2023; new partnerships including Fujifilm Vet Systems; in-house test via Heska/Antech coming soon.","Nu.Q NETs pillar advanced with FDA regulatory pathway; Capture-PCR breakthrough presented at ESMO 2023.","Conference call March 26, 2024 at 8:30 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-001451","json":"https://secwatch.observer/filing/0001477932-24-001451.json","markdown":"https://secwatch.observer/filing/0001477932-24-001451.md","text":"https://secwatch.observer/filing/0001477932-24-001451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/0001477932-24-001451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:54:22.785296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04a5d6420bb5bfa8a9bc363c36325eb7738f1b26","claim":"VOLITIONRX LTD reported the full fiscal year ended December 31, 2023 results: revenue approximately $775,000.","evidence_excerpt":"· Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022. · Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. · Received $13.0 million in milestone payments from Heska Corporation in December 2023. · Net cash used in operating activities","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/0001477932-24-001451-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full fiscal year ended December 31, 2023"},{"label":"Revenue","value":"approximately $775,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}